Aquis AQSE - Delayed Quote GBp

EDX Medical Group Plc (EDX.AQ)

10.11

-1.64

(-13.96%)

At close: 1:43:42 PM GMT+1

Medical Boost for Young Men as New, Highly Accurate Early Detection Testicular Cancer Test Launched by EDX Medical in UK

CAMBRIDGE, England, April 11, 2025--The world’s most advanced early detection test for testicular cancer – now the most common form of cancer among young men – is being launched in the UK.

Business Wire 25 days ago

EDX.AQ
-13.96%
New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX Medical

CAMBRIDGE, England, February 17, 2025--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.

Business Wire 2 months ago

EDX.AQ
-13.96%
EDX Medical Announces Agreement With Caris Life Sciences to Distribute Molecular Profiling in the United Kingdom and Nordic Countries

CAMBRIDGE, England, September 02, 2024--EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation AI TechBio and precision medicine company.

Business Wire 7 months ago

EDX.AQ
-13.96%
EDX Medical to Market Pioneering Cancer Drugs Response Assay in UK and Nordics

CAMBRIDGE, England, June 26, 2024--EDX Medical Group plc has signed an exclusive distribution agreement with Curesponse Ltd to market the cResponse™ cancer assay in the UK and Nordics.

Business Wire 10 months ago

EDX.AQ
-13.96%

Performance Overview

Return	EDX.AQ	MSCI WORLD (^990100-USD-STRD)
YTD	+13,844.83%	-0.34%
1-Year	+13,380.00%	+8.96%
3-Year	+28,378.87%	+33.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

EDX Medical Group Plc (EDX.AQ)

Medical Boost for Young Men as New, Highly Accurate Early Detection Testicular Cancer Test Launched by EDX Medical in UK

New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX Medical

EDX Medical Announces Agreement With Caris Life Sciences to Distribute Molecular Profiling in the United Kingdom and Nordic Countries

EDX Medical to Market Pioneering Cancer Drugs Response Assay in UK and Nordics

Performance Overview